Orphan immunotherapies for allergic diseases.

Area of Science:

• Allergy and Immunology
• Immunotherapy Research
• Orphan Allergens

Background:

• Allergen immunotherapy (AIT) is a clinically effective treatment for allergic diseases.
• Subcutaneous immunotherapy (SCIT) is key for severe Hymenoptera venom allergies.
• SCIT and sublingual immunotherapy (SLIT) are indicated for inhalant allergens causing allergic rhinitis and asthma.

Purpose of the Study:

• To review the current state of immunotherapy for less common allergens, termed "orphan immunotherapies."
• To highlight the limited research and availability of treatments for these allergens.
• To discuss the challenges and implications of developing "orphan immunotherapies."

Main Methods:

• Literature search of MEDLINE for English-language articles.
• Selection of randomized, controlled, masked studies for orphan immunotherapies.
• Description of available reports for other cases.

Main Results:

• Abundant literature exists for food allergen desensitization.
• Limited studies, often small or case reports, exist for orphan allergens like mosquito, Argas reflexus, dog, and occupational allergens.
• Immunotherapy for these "orphan" allergens is poorly studied and often unavailable.

Conclusions:

• Orphan immunotherapy lacks sufficient evidence of efficacy from controlled trials.
• There's an underestimation of the importance of some allergen sources.
• Commercial production of orphan allergen extracts is unlikely due to high registration costs and small patient populations.
• Adequate immunotherapy preparations should be developed for orphan allergens.